ER-PROTAC

PROteolysis TArgeting Chimera (PROTAC) is a novel technology which can simultaneously bind with disease-causing target protein (meant for degradation) and an E3-ubiquitin ligase, and thereby, induce the selective ubiquitination-proteasomal degradation of target protein.

Protac technology has a great superiority in degrading not only undruggable targets, but also mutated or overexpressed oncogene that drives the drug resistance to targeted therapeutic strategies.

EnhancedBio’s ER-Protac, is a small-molecule, orally bioavailable, potent ER degrader, selectively targets the estrogen receptor (ER) for the treatment of metastatic ER+ positive/HER2− negative breast cancer patient with unmet medical need.